Fibrocell Science, Inc. CEO Rings the New York Stock Exchange Closing Bell

Published: Jun 05, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

EXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc. (NYSE MKT: FCSC), an autologous cell therapy company focused on the development of innovative products for aesthetic, medical and scientific applications, announced today that Chief Executive Officer and Chairman David Pernock, will preside over the Closing Bell on Tuesday, June 4, 2013 at 4 p.m. Eastern Time at the New York Stock Exchange. “We are pleased that the New York Stock Exchange has given Fibrocell the honor of ringing the Closing Bell. This occasion marks the successful listing of our stock on the NYSE MKT,” Pernock said. “We are focused on expanding the applications of our FDA-approved product, LAVIV® (azficel-T), to areas of significant unmet medical needs such as restrictive burn scarring, vocal cord scarring and acne scarring.”

Help employers find you! Check out all the jobs and post your resume.

Back to news